JLABS and Merck Discussion Panel Event

Tuesday, May 15 and Thursday, May 17

Join us and your peers for this event to discuss challenges when transitioning from pre-clinical to clinical.

Snacks and refreshments will be served.

Snacks and refreshments will be served.

Abstract

It is critical to anticipate and overcome challenges rapidly when transitioning from pre-clinical POC studies into clinical studies in drug development. The earlier you consider the risks and long-term effects of raw materials, technologies and process performance, the higher your chances of succeeding in development.

Key considerations regarding raw materials, supply chain robustness, technology scalability and validation requirements are often underestimated. However, if one of these areas is not properly managed, it could lead to serious project delays and can potentially compromise the development and commercialization of pioneering drug therapies.

This presentation and subsequent panel discussion will:

• Bring to light the challenges encountered when going from animal testing to first-in-human studies
• Consider factors which can mitigate potential pitfalls
• Share ideas on how to facilitate a seamless transition